pharmaphorum January 22, 2026
Medicines for obesity, diabetes, rare diseases, cancer, and women’s health feature among Clarivate’s annual round-up of 11 Drugs to Watch this year, but two of them far outstrip the others in sales potential.
There are no prizes for guessing that the multibillion-dollar predictions go to GLP-1-based therapies for obesity and type 2 diabetes, given the class has dominated the pharma news agenda in the last couple of years. But while the current market is a duopoly dominated by Novo Nordisk and Eli Lilly, Clarivate sees one clear winner in its sales projects in the G7 markets (Canada, France, Germany, Italy, Japan, the UK, and the US) in 2031.
As we can see from the list below – which considers both...
Today's Sponsors
Today's Sponsor